Intravenous TAT-Bcl-XL is protective after middle cerebral artery occlusion in mice

Annals of Neurology

Volumn 52, Issue 5, 2002, Pages 617-622

  Kilic, Ertugrul ^a   Dietz, Gunnar P H ^a   Hermann, Dirk M ^b   Bähr, Mathias ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; DNA FRAGMENT; HYBRID PROTEIN; TAT BCL XL FUSION PROTEIN; TAT BETA GALACTOSIDASE FUSION PROTEIN; TAT GFP FUSION PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOCHEMISTRY; BLOOD BRAIN BARRIER; BRAIN INFARCTION; BRAIN ISCHEMIA; BRAIN TISSUE; CELL MEMBRANE PERMEABILITY; CELL VIABILITY; CONTROLLED STUDY; CORPUS STRIATUM; DNA DAMAGE; DOSE TIME EFFECT RELATION; DRUG BRAIN LEVEL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; ENZYME BINDING; FUTUROLOGY; HUMAN IMMUNODEFICIENCY VIRUS; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; MOUSE; NERVE CELL; NEUROLOGIC DISEASE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN ENGINEERING; PROTEIN STRUCTURE; TISSUE DISTRIBUTION;

ANIMALS; BCL-X PROTEIN; BRAIN; CASPASE 3; CASPASES; CEREBROVASCULAR CIRCULATION; DRUG ADMINISTRATION SCHEDULE; ENZYME ACTIVATION; GENE PRODUCTS, TAT; INFARCTION, MIDDLE CEREBRAL ARTERY; LASER-DOPPLER FLOWMETRY; MALE; MICE; MICE, INBRED C57BL; NERVOUS SYSTEM DISEASES; NEUROPROTECTIVE AGENTS; PROTO-ONCOGENE PROTEINS C-BCL-2; RECOMBINANT FUSION PROTEINS; TIME FACTORS;

EID: 0036829818     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.10356     Document Type: Article

References (23)

1. Bähr M. Live or let die-retinal ganglion cell death and survival during development and in the lesioned adult CNS. Trends Neurosci 2000;23:483-490.
2. Hermann DM, Kilic E, Kügler S, et al. Adenovirus-mediated GDNF and CNTF pretreatment protects against striatal injury following middle cerebral artery occlusion in mice. Neurobiol Dis 2001;8:655-666.
3. Hatal R, Maeda K, Hermann D, et al. Evolution of brain infarction after transient focal cerebral ischemia in mice. J Cereb Blood Flow Metab 2000;20:937-946.
4. Hermann DM, Kilic E, Hata R, et al. Relationship between metabolic changes, gene responses and delayed ischemic injury after mild focal cerebral ischemia in mice. Neuroscience 2001;104:947-955.
5. Frankel AD, Pabo CO. Cellular uptake of the Tat protein from human immunodeficiency virus. Cell 1988;55:1189-1193.
6. Green M, Loewenstein PM. Autonomous functional domains of chemically synthesized human immunodeficiency virus Tat trans-activator protein. Cell 1988;55:1179-1188.
7. Schwarze SR, Ho A, Vocero-Akbani BA, Dowdy SF. In vivo protein transduction: Delivery of a biologically active protein into the mouse. Science 1999;285:1569-1572.
8. L is an antiapoptotic regulator for postnatal CNS neurons. J Neurosci 1998;18:1009-1019.
9. Minn AJ, Velez P, Schendel SL, et al. Bcl-x(L) forms an ion channel in synthetic lipid membranes. Nature 1997;385:353-357
10. Adams JM, Cory S. The Bcl-2 protein family: Arbiters of cell survival. Science 1998;281:1322-1326.
11. Schulz JB, Weller M, Moskowitz MA. Caspases as treatment targets in stroke and neurodegenerative disease. Ann Neurol 1999;45:421-429.
12. Reed JC. Double identity for proteins of the Bcl-2 family. Nature 1997;387:773-776.
13. Kip1 induces cell migration. Nat Med 1998;4: 1449-1452.
14. Kilic E, Hermann DM, Hossmann KA. Recombinant tissue plasminogen activator reduces infarct size after reversible thread occlusion of middle cerebral artery in mice. NeuroReport 1999;10:107-111.
15. Scheld WM. Drug delivery to the central nervous system: General principles and relevance to therapy for infections of the central nervous system. Rev Infect Dis 1989;11:S1669-S1690.
16. Egleton RD, Davis TP. Bioavailability and transport of peptides and peptide drugs into the brain. Peptides 1997;18:1431-1439.
17. Van de Waterbeemd H, Camenisch G, Folkers G, et al. Estimation of blood-brain barrier crossing of drugs using molecular size and shape, and H-bonding descriptors. J Drug Target 1998;6:151-165.
18. Fawell S, Seery J, Daikh Y, et al. Tat-mediated delivery of heterologous proteins into cells. Proc Natl Acad Sci USA 1994;91:664-668.
19. L but not Bcl-2 genes reduces lesion size after permanent middle cerebral artery occlusion in mice. Neurosci Lett 1999;268:119-122.
20. Schendel SL, Xie Z, Montal MO, et al. Channel formation by antiapoptotic protein Bcl-2 . Proc Nad Acad Sci USA 1997;94:5113-5118.
21. Shimizu S, Eguchi Y, Kamiike W, et al. Bcl-2 prevents apoptotic mitochondrial dysfunction by regulating proton flux. Proc Nad Acad Sci USA 1998;95:1455-1459.
22. L protects astrocytes from glucose deprivation and is associated with higher glutathione, ferritin, and iron levels. Anesthesiology 1999;91:1036-1046.
23. Hossmann KA. Glutamate-mediated injury in focal cerebral ischemia: The exitotoxin hypothesis revised. Brain Pathol 1995;4:23-36.